Business Context and Reporting Period
Company: Bond Laboratories, Inc. (Note: Metadata lists "FITLIFE BRANDS, INC." but the filing text identifies the registrant as Bond Laboratories, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: April 20, 2009
Reporting Period: Events occurring on December 31, 2008, April 15, 2009, and April 20, 2009.
Key Financial Metrics and Capital Structure
This filing details capital raising activities rather than operational financial performance. Specific revenue, profit, or cash flow figures for the period are not provided in this text.
- Series B Preferred Stock Financing (Initial): Issued 125 shares on Dec 31, 2008, for gross proceeds of $1.25 million.
- Series B Preferred Stock Financing (Current): Issued 78.3 shares on April 20, 2009, to approximately 10 investors for gross proceeds of $783,000.
- Common Stock Issuance: 7,500,000 shares issued in connection with the initial Series B financing.
- Debt/Liquidity Facility: Entered a 12-month Line of Credit with U.S. Bancorp on April 15, 2009.
- Line of Credit Terms: Up to $250,000 secured by inventory; interest rate of 3.5% plus one-month Libor (minimum 4.5%).
Material Changes and Agreements
The filing reports the entry into material definitive agreements regarding equity and debt financing:
- Preferred Stock Terms: The Series B Preferred Stock carries a 10% cumulative perpetual dividend rate on the $10,000 stated value per share. It is non-convertible and ranks senior to Common Stock and Series A Convertible Preferred Stock upon liquidation.
- Use of Proceeds: Funds from the Series B Financing are designated for working capital purposes.
- Restrictions: The company is prohibited from creating equity securities ranking senior or pari-passu to the Series B Shares without the consent of three-fourths of Series B holders.
Guidance, Risks, and Contingencies
Forward-Looking Statements: The filing includes a cautionary note stating that projections regarding operations, cash flows, and financial condition are subject to risks and uncertainties. Actual results may differ materially from expectations.
Unregistered Sales: The securities were sold in a private placement to accredited investors under Section 4(2) of the Securities Act and Rule 506 of Regulation D, without general solicitation.
Management Commentary: No specific operational outlook or earnings guidance is provided in this text beyond the general forward-looking disclaimer.
Key Facts for Investor Verification
- Verify the total outstanding amount of Series B Preferred Stock and accrued dividends as of the current date.
- Confirm the utilization status of the $250,000 U.S. Bancorp Line of Credit secured by inventory.
- Review the impact of the 10% cumulative dividend obligation on future cash flow requirements.
- Check subsequent filings for any changes in the company's name or status, given the discrepancy between the metadata ("FITLIFE BRANDS, INC.") and the filing text ("Bond Laboratories, Inc.").